Bruce Brook of CSL in second quartile of Large MCap Director Scorecard for past year
Bruce Brook's performance as Director of CSL is ranked in the second quartile of BuySellSignals News Bites' Large MCap performers for the past year; a percentile ranking of 51.9. The shares were up 8.7% in AUD terms for the year ended August 21, 2019. In USD terms the price rise was 0.9%.
SECTION 1 BIOGRAPHY BRUCE BROOK, INDEPENDENT NON-EXECUTIVE DIRECTOR
Mr Bruce Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Boart Longyear Limited, Lihir Gold Limited and Consolidated Minerals Limited. During his executive career, he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.
Mr Brook is Chairman of the Audit and Risk Management Committee and a member of the Nomination Committee.
Cash salary and fees Total 2013: $ 213,582
SECTION 2 CSL LIMITED ACTIVITIES
CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protectpublic health and help people with life-threatening medical conditions live full lives. The operational businesses include CSL Behring and Seqirus provides life saving products to more than 60 countries and employs 22,000 people. The Group operates predominantly in Australia, the USA, Germany, the United Kingdom and Switzerland.
SECTION 3 OTHER DIRECTORS OF CSL LIMITED
Paul Perreault, Chief Executive Officer & Managing Director
David Lamont, Chief Financial Officer
Megan Clark, Director
David Anstice, Director
Tadataka Yamada, Director
Christine OReilly, Independent Director
Marie McDonald, Independent Director
Bruce Brook, Independent Non-Executive Director
Brian McNamee, Independent Non-Executive Director
Abbas Hussain, Independent Non-Executive Director
Paul McKenzie, Chief Operating Officer
Ed Bailey, Company Secretary
Fiona Mead, Company Secretary
SECTION 4 RECENT NEWS ON DIRECTORS
4.1 SHAREHOLDER VALUE ADDED BY DIRECTORS
01 July 2019
Paul Perreault brings four-bagger value to CSL
Paul Perreault was appointed CEO of CSL (ASX:CSL) six years ago on July 01, 2013. The present value of AUD1,000 (PV1000) invested on the appointment date is $A4,308, for a capital gain of $A2,912 and dividend reinvested of $A395. In the same period the shares were up 291.2% from $A55.4 to $A216.6.
SECTION 5 CSL LIMITED PRICE PERFORMANCE SCORECARD (Australian:CSL):
5.1 The Past Four Years
CSL rises for a fourth consecutive year, a four-year rise of 177%
CSL Limited (ASX:CSL), extended its rise from 19.3% three years ago to 75.2% two years ago to 8.7% a year ago. In the past four years it has risen $A150.30 (176.8%), compared with the All Ordinaries Index which rose 1,347.8 points (25.8%) in the four years for a relative price increase of 151.0%.
5.2 Moving Annual Return (Past 5 years)
Based on a dynamic start date of 5 years ago, the real rate of return has averaged 31.7%. The Moving Annual Return has consistently exceeded 9%.
|CSL||Close (AUD)||Dividends (AUD)||Capital Gain %||% Yield||Annual Return %|
|1 Yr ago||216.38||1.92||72.5||1.5||74.1|
|2 Yrs ago||125.42||1.72||21.1||1.7||22.7|
|3 Yrs ago||103.58||1.71||19.4||2||21.4|
|4 Yrs ago||86.74||1.39||28.5||2.1||30.6|
Close 5 years ago $A67.49
5.3 Present Value of $A1000 invested in the past
The present value of $A1000 invested a year ago is $A1,101
|All Ordinaries Index||987||949||1,030|
5.4 Trailing Price Change %
1-Year price change of 8.7% for CSL outperformed the change of 2.1% in the All Ordinaries Index for a relative price change of 6.6%.
|Price Change %||1-Month||3-Month||1-Year|
|Pharmaceuticals & biotechnology sector||4.0||13.5||9.4|
|All Ordinaries Index||-3.1||-0.2||2.1|
SECTION 6 CSL LIMITED FINANCIALS AND GROWTH PERFORMANCE SCORECARD (Australian:CSL):
6.1 Key Financials (All figures percent)
EPS Growth has improved from -7.7% in 2016 to 11.0% in 2019 and Operating Margin has improved from 26.6% in 2016 to 28.5% in 2019.
|CSL||Revenue Growth||EPS Growth||Operating Margin||ROE|
6.2 Revenue and Net Profit
In the last 3 years Compound Annual Growth Rate (CAGR) averaged 10.3% for Total Revenue and 13.5% for Net Profit.
|Description||Annual ($US B)||3-year Avg ($US B)||3-year CAGR %|
CAGR = Compound Annual Growth Rate
6.3 Performance (All figures in %)
Net Profit Margin 3-year average is 21.8% and Return on Assets 3-year average is 15.4%.
|Operating Profit Margin||28.5||27.6|
|Net Profit Margin||23.4||21.8|
|Return on Equity||36.5||40.4|
|Return on Assets||15.6||15.4|
|Return on Capital Employed||23.1||23.8|
6.4 High Performance Indicators and rank of CSL in the Australian market:
|Description||CSL Value||Rank In Australian Market|
|Turnover in Quarter||$A10.2 billion||In Top 1%|
|Return on Assets [ROA] %||15.6||In Top Quartile|
|Price/MAP200||1.18||In Top Quartile|
|Return on Capital Employed [ROCE] %||23.1||In Top Quartile|
|Volatility %||1.4||In Top Quartile|
|Price/MAP50||1.06||In Top Quartile|
SECTION 7 CSL LIMITED GLOBAL RANK (Australian:CSL):
7.1 Global Rank
Rank in the All Ordinaries Index [out of 493 stocks]
|Total Assets (US$)||12.3B||29|
|Net Profit (US$)||1.8B||8|
|Return on Equity %||36.5||20|
|Net Profit Margin %||23.4||95|
|Price to Book||21.4||376|
|PV$1000 (1Year) US$*||1,021||213|
|% Change YTD||27.9||143|
Aug 21, 2019: AUD 1 equals USD 0.6782